Endocrine Abstracts

Background: Gender-affirming hormone treatment (GAHT) is the cornerstone in the therapeutic management of transgender and gender diverse (TGD) people, which are currently classified as transgender assigned-female-at birth (t-AFAB) and assigned-male-at birth (t-AMAB) subjects. Due to its hormonal nature, GAHT is commonly handled by the endocrinologist and available guidelines on this topic mimic the recommendations for cis-gender hypogonadal populations. However, the GAHT long ...